VAXCYTE, INC. Increase (Decrease) in Accrued Liabilities
VAXCYTE, INC. (PCVX) reported Increase (Decrease) in Accrued Liabilities of -$9.37 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-05
- VAXCYTE, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $6.20M, a 106.64% increase year-over-year.
- VAXCYTE, INC. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$15.57M.
- VAXCYTE, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was $7.30M.
- VAXCYTE, INC. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $65.00K, a 99.25% decline year-over-year.
- VAXCYTE, INC. increase (decrease) in accrued liabilities for fiscal 2025 was $5.97M.
- VAXCYTE, INC. increase (decrease) in accrued liabilities for fiscal 2024 was -$35.65M, a 198.23% decline from fiscal 2023.
- VAXCYTE, INC. increase (decrease) in accrued liabilities for fiscal 2023 was $36.30M, a 406.14% increase from fiscal 2022.
- VAXCYTE, INC. increase (decrease) in accrued liabilities for fiscal 2022 was $7.17M, a 54.85% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$9.37M 10-Q · filed 2026-08-05 | -$2.08M derived: sum of 3 quarters · filed 2026-08-05 | -$2.01M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$15.57M 10-Q · filed 2026-05-06 | -$8.28M derived: sum of 2 quarters · filed 2026-05-06 | -$8.21M derived: sum of 3 quarters · filed 2026-05-06 | -$5.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $7.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $7.36M derived: sum of 2 quarters · filed 2026-02-24 | $10.36M derived: sum of 3 quarters · filed 2026-08-05 | $5.97M 10-K · filed 2026-02-24 |
| 2025-09-30 | $65.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $3.06M derived: sum of 2 quarters · filed 2026-08-05 | -$1.33M 10-Q · filed 2025-11-04 | -$10.65M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $3.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$1.39M 10-Q · filed 2026-08-05 | -$10.71M derived: sum of 3 quarters · filed 2026-08-05 | -$2.08M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$4.39M 10-Q · filed 2026-05-06 | -$13.71M derived: sum of 2 quarters · filed 2026-05-06 | -$5.08M derived: sum of 3 quarters · filed 2026-05-06 | -$35.69M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$9.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$684.00K derived: sum of 2 quarters · filed 2026-02-24 | -$31.30M derived: sum of 3 quarters · filed 2026-02-24 | -$35.65M 10-K · filed 2026-02-24 |
| 2024-09-30 | $8.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$21.98M derived: sum of 2 quarters · filed 2025-11-04 | -$26.33M 10-Q · filed 2025-11-04 | $10.47M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$30.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$34.97M 10-Q · filed 2025-08-06 | $1.84M derived: sum of 3 quarters · filed 2026-02-24 | -$900.00K derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$4.35M 10-Q · filed 2025-05-07 | $32.45M derived: sum of 2 quarters · filed 2026-02-24 | $29.71M derived: sum of 3 quarters · filed 2026-02-24 | $28.90M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $36.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $34.07M derived: sum of 2 quarters · filed 2026-02-24 | $33.26M derived: sum of 3 quarters · filed 2026-02-24 | $36.30M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$2.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$3.55M derived: sum of 2 quarters · filed 2024-11-05 | -$511.00K 10-Q · filed 2024-11-05 | $1.18M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$812.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $2.23M 10-Q · filed 2024-08-06 | $3.92M derived: sum of 3 quarters · filed 2025-02-25 | $7.84M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $3.04M 10-Q · filed 2024-05-08 | $4.73M derived: sum of 2 quarters · filed 2025-02-25 | $8.65M derived: sum of 3 quarters · filed 2025-02-25 | $10.95M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $1.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $5.61M derived: sum of 2 quarters · filed 2025-02-25 | $7.91M derived: sum of 3 quarters · filed 2025-02-25 | $7.17M 10-K · filed 2025-02-25 |
| 2022-09-30 | $3.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $6.21M derived: sum of 2 quarters · filed 2023-11-06 | $5.48M 10-Q · filed 2023-11-06 | $1.66M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $2.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.56M 10-Q · filed 2023-08-08 | -$2.26M derived: sum of 3 quarters · filed 2024-02-27 | $2.67M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$737.00K 10-Q · filed 2023-05-08 | -$4.55M derived: sum of 2 quarters · filed 2024-02-27 | $373.00K derived: sum of 3 quarters · filed 2024-02-27 | $2.75M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$3.82M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.11M derived: sum of 2 quarters · filed 2024-02-27 | $3.49M derived: sum of 3 quarters · filed 2024-02-27 | $4.63M 10-K · filed 2024-02-27 |
| 2021-09-30 | $4.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $7.31M derived: sum of 2 quarters · filed 2022-11-07 | $8.45M 10-Q · filed 2022-11-07 | $9.24M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $2.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $3.52M 10-Q · filed 2022-08-08 | $4.31M derived: sum of 3 quarters · filed 2023-02-27 | $3.74M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $1.14M 10-Q · filed 2022-05-09 | $1.93M derived: sum of 2 quarters · filed 2023-02-27 | $1.36M derived: sum of 3 quarters · filed 2023-02-27 | $2.10M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $791.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $215.00K derived: sum of 2 quarters · filed 2023-02-27 | $962.00K derived: sum of 3 quarters · filed 2023-02-27 | $2.21M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$576.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $171.00K derived: sum of 2 quarters · filed 2021-11-10 | $1.42M 10-Q · filed 2021-11-10 | $529.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $747.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | $1.99M 10-Q · filed 2021-08-11 | $1.10M derived: sum of 3 quarters · filed 2022-02-28 | $2.67M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $1.25M 10-Q · filed 2021-05-11 | $358.00K derived: sum of 2 quarters · filed 2022-02-28 | $1.92M derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | -$887.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $675.00K derived: sum of 2 quarters · filed 2022-02-28 | $718.00K 10-K · filed 2022-02-28 | |
| 2019-09-30 | $1.56M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.60M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $43.00K 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $73.00K 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |